Dongkook Pharmaceutical stock: Q3 revenue rises 14.1%
Published on 11/17/2026 at 03:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRevenue Growth Meets Profit Pressure
- Dongkook Pharmaceutical's nine-month revenue reached 768.6 billion won as overseas health and beauty sales expanded.
- Weakness at Dongkook Life Science weighed on consolidated profitability during the third quarter.
- Centellian24 is expanding through retailers in North America, Japan and Europe.
Dongkook Pharmaceutical reported stronger sales but weaker quarterly operating profit in a regulatory filing on Monday, November 16, as international demand for its health and beauty products continued to build. Seoul Economic Daily reported that consolidated third-quarter revenue rose 14.1 percent year over year to 258.7 billion won, while operating profit fell 4.1 percent to 23.8 billion won.
International Beauty Drives Sales
For the first nine months, consolidated revenue rose 12.4 percent to 768.6 billion won and operating profit increased 6.9 percent to 77.2 billion won. Standalone revenue climbed 17.2 percent to 658.6 billion won, while standalone operating profit advanced 23.3 percent to 70.9 billion won.
The health and beauty business led the expansion. Dongkook Pharmaceutical has added Costco, Ulta Beauty and Nordstrom in the United States, entered about 7,500 stores in Japan and expanded into the United Kingdom through Boots. Madeca Cream, the flagship Centellian24 product, passed 100 million cumulative units sold in September.
Subsidiary Weakness Limits Earnings
Dongkook Life Science remained a drag on consolidated results. Its medical equipment business faced weaker diagnostic-equipment demand, while restructuring costs included the relocation of a contrast-agent plant intended to support global exports.
The prescription-drug business also contributed to the nine-month performance, with revenue up 8.4 percent. Uresco, a treatment for benign prostatic hyperplasia, secured more than 70 percent of the market for products with the same active ingredient within 10 months of its launch, and Dongkook Pharmaceutical signed a licensing and supply agreement with Spain's Faes Farma for Latin America.
Management said it plans to pursue commercialization of Lorelin, a prostate cancer treatment using its drug-delivery technology, while continuing development of treatments for obesity and acromegaly. The company is also targeting further international distribution for its health and beauty portfolio.
Dongkook's Business Profile
Dongkook Pharmaceutical develops and sells prescription and over-the-counter medicines, health supplements, medical products and health and beauty brands. Its portfolio includes Insadol, Pansidil and Centellian24, with operations centered in South Korea and expanding sales across North America, Japan and Europe. The company also develops drug-delivery technologies and specialty pharmaceutical products.
Dongkook Pharmaceutical at a Glance
- Company: Dongkook Pharmaceutical Co., Ltd.
- ISIN: KR7086450004
- Local ticker: 086450
- Primary market: KOSDAQ, South Korea
- Key brands: Centellian24, Madeca Cream, Insadol and Pansidil
South Korean equities provide the broader market setting for Dongkook Pharmaceutical stock through the KOSPI market environment.
